Organoids and organ-on-chip (OoC) are new and emerging technologies (NESTs) that are promised to bring great improvements to clinical practice in the form of personalized or precision medicine (PM). “Traditional” health technology assessments (HTAs) have in the past been focused on assessing the clinical evidence for technologies that already exist and have been studied in trials, but such a methodology runs into problems when assessing technologies that so far mostly exist as visions for the future. This takes another kind
of amended health technology assessment method. In this report we develop such a technology assessment method for assessing organoids and OoCs as emerging technologies used directly in patient management in the clinic. We search for and review a heterogeneous literature on how to assess NESTs and scientific visions, extract from this literature methodological elements that suit our purpose and add fitfor-purpose elements that we could not find in the literature. The developed vision assessment method is both intended as for the next (D2.4) HYBRIDA report, where we apply it to assess visions for clinical applications of organoids and OoCs
in PM, and as a contribution to methodological development in health technology more generally.